Literature DB >> 19582578

Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.

Ludger Leifeld1, Christoph Clemens, Jörg Heller, Jonel Trebicka, Tilman Sauerbruch, Ulrich Spengler.   

Abstract

OBJECTIVES: Urotensin II [U-II] plasma levels are increased in liver cirrhosis [LC] and are discussed as an important mediator of portal hypertension since the U-II antagonist palosuran has beneficial effects on portal hypertension by increasing splanchnic resistance. Nevertheless, no data are available on the intrahepatic expression of U-II and its receptor [UT] in humans.
METHODS: U-II and UT expression were analyzed in the livers of patients with LC, fulminant hepatic failure [FHF], and normal controls [NC] using immunohistochemistry.
RESULTS: Both U-II and UT were expressed in the liver on endothelial cells from arteries, veins, and bile ducts as well as on Kupffer cells. In LC, the total number of U-II-expressing cells was 20% lower compared to NC (P < 0.001), while expression of UT did not differ between LC and NC. In contrast, significant enhanced number of U-II and UT positive cells were found in FHF compared to LC and NC (P < 0.001). U-II and UT expression was also found in portal veins, without differences between LC and NC.
CONCLUSIONS: Our data demonstrate that U-II and UT are not elevated in human cirrhotic livers but are in livers of patients with FHF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582578     DOI: 10.1007/s10620-009-0875-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.

Authors:  Thomas Dschietzig; Cornelia Bartsch; Rainer Pregla; Heinz Robert Zurbrügg; Franz Paul Armbruster; Christoph Richter; Michael Laule; Elfrun Romeyke; Charlotte Neubert; Wolfgang Voelter; Gert Baumann; Karl Stangl
Journal:  Regul Pept       Date:  2002-12-31

3.  Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure.

Authors:  L Leifeld; C Trautwein; F L Dumoulin; M P Manns; T Sauerbruch; U Spengler
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.

Authors:  F E Bottrill; S A Douglas; C R Hiley; R White
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1.

Authors:  Mika Matsushita; Masayoshi Shichiri; Nozomi Fukai; Naoko Ozawa; Takanobu Yoshimoto; Nobuyuki Takasu; Yukio Hirata
Journal:  Endocrinology       Date:  2003-05       Impact factor: 4.736

6.  The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma.

Authors:  Magdalena Birker-Robaczewska; Céline Boukhadra; Rolf Studer; Célia Mueller; Christoph Binkert; Oliver Nayler
Journal:  J Recept Signal Transduct Res       Date:  2003       Impact factor: 2.092

7.  Urotensin II in chronic liver disease: in vivo effect on vascular tone.

Authors:  William Kemp; Stuart Roberts; Paul A Komesaroff; Ella Zomer; Henry Krum
Journal:  Scand J Gastroenterol       Date:  2008-01       Impact factor: 2.423

8.  Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes.

Authors:  Jean-Pierre Segain; Malvyne Rolli-Derkinderen; Nadine Gervois; Diane Raingeard de la Blétière; Gervaise Loirand; Pierre Pacaud
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

9.  Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.

Authors:  Jonel Trebicka; Ludger Leifeld; Martin Hennenberg; Erwin Biecker; Andreas Eckhardt; Nicolas Fischer; Andrea Schulze Pröbsting; Christoph Clemens; Frank Lammert; Tilman Sauerbruch; Jörg Heller
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

10.  Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.

Authors:  Douglas G Johns; Zhaohui Ao; Diane Naselsky; Christopher L Herold; Kristeen Maniscalco; Lea Sarov-Blat; Klaudia Steplewski; Nambi Aiyar; Stephen A Douglas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-30       Impact factor: 3.000

View more
  4 in total

1.  Effects of urotensin-II on cytokines in early acute liver failure in mice.

Authors:  Liang-Ming Liu; Liang Zhao; Dong-Yu Liang; Fang-Ping Yu; Chang-Gen Ye; Wen-Juan Tu; Tong Zhu
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

2.  The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells.

Authors:  Liang Ming Liu; Dong Yu Liang; Chang Gen Ye; Wen Juan Tu; Tong Zhu
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

3.  Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice.

Authors:  Dong-yu Liang; Liang-ming Liu; Chang-gen Ye; Liang Zhao; Fang-ping Yu; De-yong Gao; Ying-ying Wang; Zhi-wen Yang; Yan-yan Wang
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

4.  IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure.

Authors:  Liang-Ming Liu; Wen-Juan Tu; Tong Zhu; Xiao-Ting Wang; Zhi-Li Tan; Huan Zhong; De-Yong Gao; Dong-Yu Liang
Journal:  Oncotarget       Date:  2016-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.